Kyowa Kirin 대차 대조표 상태

재무 상태 기준 확인 6/6

Kyowa Kirin 의 총 주주 지분은 ¥835.2B 이고 총 부채는 ¥0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 ¥1,042.0B 및 ¥206.7B 입니다. Kyowa Kirin 의 EBIT는 ¥108.1B 이며 이자보상배율은 48.1 입니다. ¥302.4B 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

JP¥0

부채

이자 보상 비율	48.1x
현금	JP¥302.38b
주식	JP¥835.25b
총 부채	JP¥206.72b
총 자산	JP¥1.04t

최근 재무 상태 업데이트

업데이트 없음

Recent updates

What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You

Oct 22

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 03

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27

재무 상태 분석

단기부채: 4151 의 단기 자산 ( ¥548.7B )이 단기 부채( ¥155.7B ).

장기 부채: 4151 의 단기 자산( ¥548.7B )이 장기 부채( ¥51.0B ).

부채 대 자본 내역 및 분석

부채 수준: 4151 부채가 없습니다.

부채 감소: 4151 5년 전에 부채가 없었습니다.

부채 범위: 4151 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 4151 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Kyowa Kirin 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

What Kyowa Kirin Co., Ltd.'s (TSE:4151) P/E Is Not Telling You

Investor sentiment deteriorates as stock falls 17%

Kyowa Kirin Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Here's Why Kyowa Kirin (TSE:4151) Has Caught The Eye Of Investors

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors

Now 20% undervalued after recent price drop

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥23.00 per share

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Third quarter 2021 earnings released: EPS JP¥14.58 (vs JP¥18.04 in 3Q 2020)